| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 10/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| CAS Number | 49562-28-9 |
| Molecular Formula | C20H21ClO4 |
| Molecular Weight | 360.83 |
| Product Name | Fenofibrate |
| Chemical Name | 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester |
| CAS Number | 49562-28-9 |
| Storage | Keep tightly closed in light-resistant containers |
| Usage | It is used to reduce cholesterol levels in patients at risk of cardiovascular disease |
| Packaging Detail | 25kg/drum or according to your requirement |
| Delivery Detail | Within one week after payment confirmed |
Diet therapy for the treatment of adult undesirable effect hypercholesterolemia (IIa type), endogenous hypertriglyceridemia, simple type (IV type) and mixed (IIb and III). Especially applicable to high-density lipoprotein and low-density lipoprotein in patients with moderately elevated in patients with dyslipidemia characterized, and type 2 diabetes mellitus hyperlipidemia
| Items | Standard |
| Appearance | White or slightly yellow, crystalline powder |
| Solubility | Practically insoluble in water, freely soluble in anhydrous ethanol |
| Melting point | 116 - 118ºC |
| Identification | IR: Should be identical to that of RS |
| Appearance of solution | Clear, not more than BY4 |
| Water | ≤0.5% |
| Chlorides | ≤350ppm |
| Sulphated ash | ≤0.1% |
| Related substances | Impurity A≤0.1% Impurity B≤0.2% Impurity C≤0.1% Impurity D≤0.1% Impurity E≤0.8% Any other impurity ≤0.1% Total of other impurities ≤0.5% |
| Assay | 99%-101%(anhydrous substance) |
Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein(HDL) levels and reducing triglyceride levels. It is used alone or along with statins in the treatment ofhypercholesterolemia and hypertriglyceridemia.
Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus, and firstly indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy in Australia. It also appears to be helpful in decreasing amputations of the lower legs in this same group of people. Fenofibrate also has an off-label use as an added therapy of high blood uric acid levels in people who have gout.
){kind=link}